Articles

Open access, open innovation

What did open-access once mean in scientific literature, what does it mean now and how does it all play into innovation and the future of science?
Written byPeter Kissinger
| 3 min read

You are now reading an open-access publication. Decades ago, we went to a library and used a card catalog and bound indices such as Chemical Abstracts to identify scholarly works. We could then pull volumes off the shelves and gain enlightenment at a study carrel desk. Some of you will remember those. Later, we could even copy articles of special interest, or order them from a library assistant. Students at the time held printed material in high regard. We wanted to be able to contribute, and a first accepted paper was a welcomed transition to a very special club

While access was open via top-tier technical libraries, access for most citizens of this world was very restricted. The restriction reflected cost. The cost of access reflected the cost of production and only places in academia, government and commercial R&D could afford it.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Published In

Volume 13 - Issue 12 | December 2017

December 2017

December 2017 Issue

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
3D illustration of a membrane protein embedded within a lipid nanodisc, representing a native-like environment used for membrane protein stabilization and characterization.
Mass photometry supports membrane protein characterization by providing rapid insights into sample composition, purity, and molecular assembly.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue